Research Analysts’ upgrades for Tuesday, August 8th:

Acco Brands Corporation (NYSE:ACCO) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

Ares Commercial Real Estate Corporation (NYSE:ACRE) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

Agree Realty Corporation (NYSE:ADC) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Armada Hoffler Properties (NYSE:AHH) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Alon USA Partners, (NYSE:ALDW) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

Anika Therapeutics (NASDAQ:ANIK) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

American Express (NYSE:AXP) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

Aspen Technology (NASDAQ:AZPN) was upgraded by analysts at BidaskClub from a buy rating to a strong-buy rating.

BB&T Corporation (NYSE:BBT) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Banco Bilbao Vizcaya Argentaria SA (NASDAQ:BBVA) was upgraded by analysts at BidaskClub from a buy rating to a strong-buy rating.

BankFinancial Corporation (NASDAQ:BFIN) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

BHP Billiton Limited (NYSE:BHP) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Over the last one month, BHP Billiton’s shares outperformed the industry. Improving iron-ore prices will likely bolster the company’s results in the quarters ahead. The company is also poised to grow on the lower costs, increased productivity and superior operations.  However, over the last 30 days, the Zacks Consensus Estimate for the stock moved south for fiscal 2018. We believe that headwinds such as stiff industry rivalry, sudden outbreak of any natural disaster or unfavorable government policies might hurt the BHP Billiton’s results in the quarters ahead.”

Beazer Homes USA (NYSE:BZH) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

CACI International (NYSE:CACI) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

Cerus (NASDAQ:CERS) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

China Telecom Corp (NYSE:CHA) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

Comerica (NYSE:CMA) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

Cinemark Holdings (NYSE:CNK) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Consolidated Communications Holdings (NASDAQ:CNSL) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Rockwell Collins (NYSE:COL) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

Computer Programs and Systems (NASDAQ:CPSI) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

Canadian Solar (NASDAQ:CSIQ) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Canadian Solar caters to a geographically diverse customer base spread across both key markets and emerging markets. It is gradually gaining share in Asia, which could soon become a major solar market. To enjoy a distinct advantage over its peers, the company has come up with a new diamond module, which has the capacity to withstand extreme weather conditions. Also, Canadian Solar outperformed the broader industry in past one year. Yet, Canadian Solar is expected to continue experiencing market dislocation in the near term, which will directly impact Canadian Solar’s 2017 financial performance. We note that, as the company has operations and projects in various geographies, it faces various geopolitical risks. Also, stiff competitions from cheaper alternatives and exposure to foreign exchange risks are added concerns.”

CSRA (NYSE:CSRA) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “CSRA is the largest pure play government IT service provider. The company’s deep domain knowledge and expertise in next-generation IT services is aiding it to win new contracts on a regular basis. Additionally, partnerships with technology companies like Microsoft, Amazon and Oracle is a key growth driver. Moreover, anticipated improvement in federal spending is a positive for the company. However, muted near-term revenue guidance due to sluggishness in award procurement and uncertainty over the renewal of TSA and Groundbreaker contracts are headwinds. The company's forecast of lower new business revenues as compared with fiscal 2017 and lower win rate remain overhang, in our view. Notably, the company has underperformed the industry on a year-to-date basis.”

Consolidated-Tomoka Land (NYSEMKT:CTO) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

CTS Corporation (NYSE:CTS) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

Curtiss-Wright Corporation (NYSE:CW) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

Dollar Tree (NASDAQ:DLTR) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Dollar Tree (NASDAQ:DLTR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $85.00 target price on the stock. According to Zacks, “Dollar Tree has outperformed the industry in the last one month. The company has been doing well on the back of its long-term strategies and growth initiatives like store expansion and productivity enhancement, tapping of new markets and adding innovative sales channels to serve its patrons better. Also, the company's idea of increasing consumables mix, rolling out freezers/coolers at stores, along with multi-price point expansion bode well. The company is also on track with Family Dollar's integration, which is expected to generate synergies in the long run. Estimates have been stable ahead of second quarter earnings. However, sales in the company's last reported quarter were somewhat dented by delayed tax refunds and SNAP benefit reductions. Well, Trump’s suggestion of reducing food stamps, and lower SNAP benefits could also hurt future performance. Additionally, management's lowered fiscal 2017 view raises concerns.”

Fitbit (NYSE:FIT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $6.50 price target on the stock. According to Zacks, “Fitbit Inc. is a manufacturer of wearable fitness tracking devices. The company reported second-quarter 2017 adjusted loss of 18 cents per share, which was narrower than the Zacks Consensus Estimate. Over the last one year, the stock has underperformed the Zacks characterised Electronic Measuring Instruments Industry. Fitbit’s growth has been slowing down with smartwatches outshining the fitness wearable category, influx of new wearables, lack of upgrades among existing users and lackluster growth in the Asia Pacific region. Management has taken some recovery initiatives that include executive shakeup and cost structuring.”

Five Below (NASDAQ:FIVE) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Foundation Medicine (NASDAQ:FMI) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

Flotek Industries (NYSE:FTK) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

Genpact Limited (NYSE:G) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $33.00 target price on the stock. According to Zacks, “Genpact is a dominant name in the Business process outsourcing (BPO) market based on its domain expertise in business analytics, digital and consulting. The company’s better-than-expected second-quarter results are driven by revenue growth from mid-teen global client BPO coupled with balanced performance across most of the targeted verticals and service lines of the company. We also note that it is gaining popularity among customers in providing emerging technologies like Blockchain and Industrial Internet of Things (IoT). Moreover, accretive acquisitions over the years have aided the company penetrate new domains like mobile technology, dynamic workflow solution and artificial intelligence (AI). Additionally, effective cost management is driving operating margin expansion. However, anticipated government regulation in the U.S. over outsourcing (H1B Visa, Cross-border tax) and high debt level are headwinds.”

Greenbrier Companies, Inc. (The) (NYSE:GBX) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

General Dynamics Corporation (NYSE:GD) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

G-III Apparel Group, LTD. (NASDAQ:GIII) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Gamestop Corporation (NYSE:GME) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “GameStop has underperformed the industry in the past three months. Dismal stock performance can primarily be attributed to the delay in launch of "Red Dead Redemption: 2" and less visibility for the demand of Nintendo Switch for the entire year, which forced management to keep its view intact despite reporting better-than-expected results in first-quarter fiscal 2017. Moreover, we noted that although the top line grew year over year, the bottom line continues to decline. The company continues to expect fiscal 2017 comps to be in the range of flat to down 5% and forecasts earnings in the range of $3.10–$3.40 per share. Meanwhile, management expects sturdy performance of Technology Brands and Collectibles to continue in fiscal 2017. Further, it expects to enhance collectibles business to approximately $650–$700 million during fiscal 2017 and anticipates becoming a $1 billion business by the end of fiscal 2019.”

Generac Holdlings (NYSE:GNRC) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

Gap, Inc. (The) (NYSE:GPS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $27.00 target price on the stock. According to Zacks, “Gap has outperformed the broader industry over the past six months, as its turnaround efforts are well on track. The company is focused on its transformation plan, and is bringing meaningful changes to its product portfolio and operating capabilities worldwide. Further, the company remains keen on streamlining its operating model by creating a more proficient global brand structure and cutting costs. These growth drivers , along with strength at its Old Navy brand helped the company to deliver a decent first-quarter that marked Gap’s fourth sales beat. However, results continued to be hurt by currency woes, a tough retail scenario and persistent weakness across Banana Republic. Currency is also expected to linger and hurt fiscal 2017 results, as is evident from Gap’s soft view. Additionally, stiff competition remains a threat. Nonetheless, Gap’s shareholder-friendly moves and focus on omnichannel development, remain noteworthy.”

Gramercy Property Trust (NYSE:GPT) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Great Plains Energy (NYSE:GXP) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Haemonetics Corporation (NYSE:HAE) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

Hannon Armstrong Sustainable Infrastructure Capital (NYSE:HASI) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Hanesbrands (NYSE:HBI) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $27.00 target price on the stock. According to Zacks, “Hanesbrands’ second-quarter 2017 sales and earnings came in line with the Zacks Consensus Estimate and increased year-over-year, driven by acquisitions and sales from online channel. The benefits from acquisitions were mainly related to Champion Europe and Hanes Australasia. Though organic sales declined in the quarter, it improved sequentially. In fact, the company expects organic sales to turn positive and contribute to growth in the second half. The company’s Project Booster program is also expected to minimize costs and increase cash flow, thus driving growth. Such factors have aided Hanesbrands’ shares to outperform the industry over the past six months. Nevertheless, the company’s performance is exposed to certain headwinds such as over reliance on premium brands, soft sales in the brick-and-mortar stores as well as unfavorable foreign currency translations.”

Herbalife LTD. (NYSE:HLF) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

Hilton Worldwide Holdings (NYSE:HLT) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

Internationa Flavors & Fragrances (NYSE:IFF) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

Inogen (NASDAQ:INGN) was upgraded by analysts at BidaskClub from a buy rating to a strong-buy rating.

Jack In The Box (NASDAQ:JACK) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

JAKKS Pacific (NASDAQ:JAKK) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “JAKKS Pacific’s second-quarter loss of $0.66 per share was much wider compared with the prior-year quarter loss of $0.27 and the Zacks Consensus Estimate of a loss of $0.24. Revenues fell 15.2% year over year to $119.6 million and lagged the consensus mark by over 9%. Notably, its earnings have been under pressure, incurring losses in eight of the 10 trailing quarters. Moreover, a challenging retail environment, adverse forex translations, age compression and the shift to alternative modes of entertainment remain threats to the top line. Even so, the company expects to gain momentum in the second half, given improved sales performance and better cost management. Also, product launches, organic growth initiatives, collaborations with popular brands and licensing agreements with famed franchises should boost sales. Yet, rising costs could weigh on margins. Shares of the company have also underperformed the industry year to date.”

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $174.00 price target on the stock. According to Zacks, “Jazz’s largest franchise is its sleep disorder portfolio. The company’s sleep disorder drug, Xyrem, is the only FDA-approved product for both cataplexy and EDS. Its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. Moreover, In Oct 2016, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, which was completed in early Apr 2017. Jazz’ shares outperformed the industry so far this year. However, Xyrem is facing patent challenges. Jazz has also been facing challenges in building sufficient inventory levels for leukemia drug Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions this year. Estimates have been stable lately ahead of the company’s Q2 earnings release.”

KEMET (NYSE:KEM) was upgraded by analysts at BidaskClub from a buy rating to a strong-buy rating.

LendingClub Corporation (NYSE:LC) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

Lindblad Expeditions Holdings (NASDAQ:LIND) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

Lincoln National Corporation (NYSE:LNC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $83.00 price target on the stock. According to Zacks, “Over the last one year, Lincoln National’s shares have outperformed the industry.  The company is well positioned for long-term growth, given its focus on reducing exposure to businesses with long-term guarantee. It has also streamlined its business by axing unprofitable and non-core lines.  In the second-quarter 2017 its earnings surpassed the Zacks Consensus Estimate and grew year over year on the back of on higher premiums, fee income, net investment income as well as other income. The stock has witnessed an upward revision in the Zacks Consensus Estimate for 2017 over the past seven days.  However, increased expense driven by investment in technology will dent margins over the next many quarters. Its declining cash flows bother.”

Macerich Company (The) (NYSE:MAC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Macerich reported a better-than-expected second-quarter 2017 funds from operations (FFO) per share. The quarter witnessed modest improvement in same-center net operating income (NOI). Moreover, taking advantage of the price dislocation in the markets, Macerich repurchased and retired 687,494 shares at an average price of $59.09. Notably, the company enjoys a premium portfolio and a presence of well-capitalized tenants in its roster. Its increasing adoption of the omni-channel model in retailing is anticipated to boost the shopping experience and enhance sales volume at tenant stores. However, increasing consumer purchases through the internet have become a pressing concern for retail REITs, including Macerich. Further, hike in interest rates remains a concern for the company. Also, shares of Macerich underperformed its industry year to date.”

Marriott International (NASDAQ:MAR) was upgraded by analysts at BidaskClub from a buy rating to a strong-buy rating.

The Medicines (NASDAQ:MDCO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $41.00 target price on the stock. According to Zacks, “The Medicines Co. has two potential blockbusters, Inclisiran and Carbavance, in different stages of development. Moreover, divestment of non-core assets to drive shareholder value is encouraging. We are also optimistic about the company’s acquisitions and in-licensing agreements to grow its pipeline. Moreover, the company’s shares have outperformed the industry in the last one year. However, the company is facing generic competition for its flagship product, Angiomax. With Angiomax sales eroding due to the presence of generics, the company’s ability to successfully develop and bring new products to the market is important for growth. Therefore, any regulatory setbacks would weigh heavily on the stock. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters.”

Magellan Health (NASDAQ:MGLN) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

MasTec (NYSE:MTZ) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $50.00 price target on the stock. According to Zacks, “MasTec reported record revenues and earnings in the second quarter with both outpacing the Zacks Consensus Estimate as well.  The better-than-expected performance can be attributed to record levels of Oil & Gas project activity. MasTec raised 2017 guidance and estimates annual revenue of approximately $6 billion and adjusted earnings per share at $2.73. The company’s recent geographic expansion of heavy civil operations, as well as entry into the water, sewer and drainage systems infrastructure market operations will provide opportunity to capitalize on the increasing demand trends in this market. In its wireline and wireless communication markets, significant expansion related to both 5G and fiber deployment will benefit its communications business. MasTec outperformed the industry in the past one year.”

NACCO Industries (NYSE:NC) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

NextEra Energy (NYSE:NEE) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

NVIDIA Corporation (NASDAQ:NVDA) was upgraded by analysts at BidaskClub from a buy rating to a strong-buy rating.

NorthWestern Corporation (NYSE:NWE) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

On Deck Capital (NYSE:ONDK) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

Oshkosh Corporation (NYSE:OSK) was upgraded by analysts at BidaskClub from a buy rating to a strong-buy rating.

Pacific Biosciences of California (NASDAQ:PACB) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

PACCAR (NASDAQ:PCAR) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

pdvWireless (NASDAQ:PDVW) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

Quanta Services (NYSE:PWR) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

QAD (NASDAQ:QADA) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

QUALCOMM (NASDAQ:QCOM) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Qualcomm continues to lead the global wireless baseband chipset market. Qualcomm gained the Taiwan Fair Trade Commission’s regulatory approval for the NXP Semiconductor buyout, but the deal is under thorough investigation by the European Commission. Qualcomm has launched its Mesh Networking Platform and seeks FCC's Approval for Antenna Pattern Testing. Qualcomm’s Snapdragon processor is known for its Internet of Things applications. Patent license network deals, tie-up with AT&T and Ericsson for 5G network trials bode well for Qualcomm’s prospects. Over the past three months, the stock price lags its industry’s performance. Further, competitive mobile phone chipset market, stringent regulatory norms along with anti-competitive and unfair business practices charges act as risks. The $1 billion dispute with Apple is getting uglier, with Apple getting the support of Silicon Valley biggies and its suppliers.”

Radius Health (NASDAQ:RDUS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “The company’s wider-than-expected loss in the second quarter was disappointing as expenses continue to increase with the launch of Tymlos. The FDA’s approval of Radius Health’s lead candidate, Tymlos, is a significant boost for the company. Although the osteoporosis market in the U.S. has a great potential as approximately 1.4 million postmenopausal women in the U.S. experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's Forteo and Amgen’s Prolia. Further, the company suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues to its MAA for Eladynos in Europe. While Radius' efforts in developing its pipeline are encouraging, we note that most of its candidates are in their early or mid stages of development. On a positive note, the company’ shares have outperformed the industry year to date.”

Rollins (NYSE:ROL) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

SBA Communications Corporation (NASDAQ:SBAC) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

SolarEdge Technologies (NASDAQ:SEDG) was upgraded by analysts at BidaskClub from a buy rating to a strong-buy rating.

Shenandoah Telecommunications (NASDAQ:SHEN) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Shire PLC (NASDAQ:SHPG) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Shire reported encouraging Q2 results, beating estimates for both sales and earnings.The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology space, acquiring roughly 23% of the total market by the end of Jun 2017. The Dyax acquisition has integrated well and Shire announced positive results from the phase III trial on lanadelumab in May 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Moreover, shares have underperformed the industry.”

Sempra Energy (NYSE:SRE) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Supreme Industries (NYSE:STS) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

TransAlta Corporation (NYSE:TAC) (TSE:TA) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Telephone and Data Systems (NYSE:TDS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $32.00 price target on the stock. According to Zacks, “Telephone and Data Systems posted disappointing second-quarter 2017 financial results, wherein both the top and bottom line missed the Zacks Consensus Estimate. Despite such weak results, we are impressed with the company’s efforts to expand its business in the managed hosting and cloud service market. Launch of Shared Data plans for consumers and businesses at nominal prices have helped the company gain consumers. The company's IPTV is also doing considerably well. The company continues to experience strong smartphone demand at its wireless wing – U.S. Cellular. Over the past three months, the stock price grew 7.93%, beating its industry's growth of 4.18%. However, intense competition, roaming revenues related woes, costs associated with network integration and construction of new cell sites, aggressive equipment pricing, wireless technology upgrades and spectrum licensing are near-term risks.”

Teledyne Technologies (NYSE:TDY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $166.00 target price on the stock. According to Zacks, “Teledyne Technologies Inc. is a leading provider of sophisticated electronic and communication products, systems engineering solutions and information technology services, and aerospace engines and components. The company customers include aerospace prime contractors, general aviation companies, government agencies and major communications and other commercial companies. “

Teledyne Technologies (NYSE:TDY) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Transportadora De Gas Sa Ord B (NYSE:TGS) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

The Hanover Insurance Group (NYSE:THG) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

Toll Brothers (NYSE:TOL) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $44.00 price target on the stock. According to Zacks, “Toll Brothers’ shares have outperformed the industry in the last one year. Strong housing demand and lack of competition in the luxury new home market is expected to drive Toll Brothers’ revenues. Also, the 2017 outlook for the U.S. homebuilding industry is quite compelling given the affordable interest rates and tight inventory indicating pent-up demand. However, we are concerned about the escalating building material and labor costs that are proving to be a drag on margins.”

Ubiquiti Networks (NASDAQ:UBNT) was upgraded by analysts at BidaskClub from a buy rating to a strong-buy rating.

Universal Health Services (NYSE:UHS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Universal Health’s robust inorganic growth has substantially contributed to strong revenue generation. Moreover, the U.S healthcare industry offers immense untapped opportunities given the rising numbers of baby boomers. Also, solid Acute-care Platform continues to perform well. However, its second-quarter 2017 earnings have missed the Zacks Consensus Estimate and remained flat year over year. Universal Health has also lowered its 2017 EPS guidance following the poor second-quarter results. The company is exposed to integration risks owing to several acquisitions. Further, its highly leveraged balance sheet is a major headwind. The company is also expected to witness margin contraction at both acute care and behavioral hospitals. Well reflective of the headwinds, over last one year, the company’s shares have significantly underperformed the broader industry.”

Univar (NYSE:UNVR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $34.00 price target on the stock. According to Zacks, “Univar Inc. is a distributor of chemicals and innovative services. The Company offers solvents, resins, pigments, acids, bases, surfactants, glycols, inorganic compounds and alcohols. It also offers transportation and warehousing infrastructure, chemicals and hazardous materials handling services. The Company’s operating geographical segments include Univar USA, Univar Canada, Univar Europe and the Middle East as well as Rest of World. It serves coatings and adhesives, food, oil and gas, personal care and pharmaceutical industries. Univar Inc. is headquartered in Downers Grove, Illinois. “

Marriot Vacations Worldwide Corporation (NYSE:VAC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $129.00 price target on the stock. According to Zacks, “Marriott Vacations Worldwide Corporation is a developer, marketer, seller and manager of vacation ownership resorts and vacation club, destination club and exchange programs, principally under the Marriott and Ritz-Carlton brands and trademarks. The Company generates most of its revenues from four primary sources: selling vacation ownership products, managing our resorts, financing consumer purchases of vacation ownership products and renting vacation ownership inventory. “

VimpelCom (NASDAQ:VEON) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “VEON Ltd. is engaged in telecommunication and digital services. It provides customers with voice, fixed broadband, data and digital services. The company’s brand portfolio includes Beeline, Kyivstar, WIND, Jazz, Banglalink and Djezzy. It operates primarily in Russia, Italy, Algeria, Pakistan, Uzbekistan, Kazakhstan, Ukraine, Bangladesh, Kyrgyzstan, Tajikistan, Armenia, Georgia and Laos. VEON Ltd, formerly known as VimpelCom Ltd., is headquartered in Amsterdam, Netherland. “

Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at Zacks Investment Research from a sell rating to a strong-buy rating. The firm currently has $18.00 price target on the stock. According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “

21Vianet Group (NASDAQ:VNET) was upgraded by analysts at BidaskClub from a strong sell rating to a sell rating.

Workday (NYSE:WDAY) was upgraded by analysts at BidaskClub from a buy rating to a strong-buy rating.

Watsco (NYSE:WSO) was upgraded by analysts at BidaskClub from a hold rating to a buy rating.

ZIOPHARM Oncology (NASDAQ:ZIOP) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.

Receive News & Ratings for Acco Brands Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acco Brands Corporation and related companies with MarketBeat.com's FREE daily email newsletter.